The cost of the pharmacological treatment for type 2 diabetic patients;Coste del tratamiento farmacológico del paciente diabético tipo 2

Semergen

Volumn 31, Issue 5, 2005, Pages 204-209

  Vernet Vernet, M ^a   Sender Palacios, M J ^b   Ramirez Gonzalez R M ^c   Lopez Lupion F X ^c   Vera Gormaz, C ^c  

^a Doctora en Medicina y Cirugia Especialista en Medicina Interna Ctro de Atencion Primaria Terrassa   (Spain)

^b Doctora en Medicina y Cirugía Especialista en Medicina de Familia   (Spain)

^c Especialista en Medicina de Familia y Comunitaria   (Spain)

Author keywords

cost; diabetes; treatment

Indexed keywords

EID: 33846388259     PISSN: 11383593     EISSN: 15788865     Source Type: Journal    
DOI: 10.1016/S1138-3593(05)72913-0     Document Type: Article

References (47)

1. King H., Aubert R.E., and Herman W.H. Global Burden of Diabetes, 1995-2025. Prevalence, numerical estimates, and projections. Diabetes Care 21 (1998) 1414-1431
2. Rubio J.A., and Álvarez J. Costes económicos de la diabetes mellitus: revisión crítica y valoración coste-eficacia de las estrategias propuestas para su reducción. Aten Primaria 22 (1998) 239-255
3. American Diabetes Association. Economic Consequences of Diabetes Mellitus in the U.S. in 1997. Diabetes Care 21 (1998) 296-309
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
5. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
6. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317 (1998) 703-713
7. Adler A.l., Stratton I.M., Neil H.AW., Yudkin J.S., Matthews D.R., Cull C.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. Br Med J 321 (2000) 412-419
8. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S., et al. Effects of intensive bloodpresure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 (1998) 1755-1762
9. Turner R.C., Frighi C.C., and Holman R.R. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281 (1999) 2005-2012
10. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 317 (1998) 713-720
11. Bakris G.L., Williams M., Dworkin L., Elliot W.J., Epstein M., Toto R., et al. Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 36 (2000) 646-661
12. Haffner S.M. Management of dyslipidemia in adults with diabetes. Diabetes Care 21 (1998) 160-178
13. Hart W.M., Espinosa C., and Rovira J. El coste de la diabetes mellitus conocida en España. Med Clin (Barc) 109 (1997) 289-293
14. Costa B., Arroyo J., and Sabaté A. The Economics of Pharmacotherapy for Diabetes Mellitus. PharmacoEconomics 11 (1997) 139-158
15. a ed. Ed. Harcourt; 2000.
16. American Diabetes Association. Standards of Medical Care for Patients with Diabetes Mellitus. Clinical Practice Recomendations. Diabetes Care 22 Supl 1 (1999) S32-41
17. López Bastida J., Serrano Aguilar P., and Duque González B. Los costes socioeconómicos de la diabetes mellitus. Aten Primaria 29 (2002) 145-150
18. Passa P.H., and Giraud S. Cost of antihypertensive treatment in diabetic patients. Diabetes Metab 19 (1993) 523-527
19. OMS. Diabetes Mellitus. Informe de un grupo de estudios de la OMS. Ginebra. Serie Informes Técnicos, n.° 727, 1985.
20. In: Krnas H.M.J., Porta M., and Keen H. (Eds). Diabetes care and Research in Europe. The St. Vincent declaration action programe. Implementation document. WHO Regional Office for Europe (1992)
21. Estacio R.O., Jeffers B.W., Gifford N., and Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23 Supl (2000) B54-64
22. Associació Catalana de Diabetis. Diabetes Mellitus (1996), Edicions El Mèdol, Tarragona p. 385-409
23. Tarnow L., Rossing P., Gall M.A., Nielsen F.S., and Parvin H.H. Prevalence of arterial hypertension in diabetic patients before and after JNC-V. Diabetes Care 17 (1994) 1247-1251
24. The Hypertension in Diabetes Study Group. Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 11 (1993) 309-317
25. Sender Palacios M.J., Vernet Vernet M., Larrosa Sáez P., Tor Figueras E., and Foz Sala M. Características sociodemográficas y clínicas de una población con diabetes mellitus. Aten Primaria 29 (2002) 474-480
26. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
27. Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
28. Curb J.D., Pressel S.L., and Cutier J.A. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 276 (1996) 1886-1892
29. Tuomilehto J., Rastenyte D., and Birtkenhäger W.H. Effects of calciumchannel blokade in older patients with diabetes and systolic hypertension. N Engl J Med 340 (1999) 677-684
30. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE sub-study. Lancet 355 (2000) 253-259
31. Estacio R.O., Jeffers B.W., Hiatt W.R., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338 (1998) 645-652
32. Lindholm L.H., Hansson L., and Ekborn T. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old patients with hypertension-2. J Hypertension 18 (2000) 1671-1675
33. Parving H.H., Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., and Arner P. The effect of ibersartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
34. American Diabetes Association. Complicaciones Cardiovasculares en Diabetes. Volumen 1 (ed. esp.). Medical Trends, SL; 2002.
35. Delgado R., and Aguilera A. Los antagonistas de los receptores de la angiotensina II (ARA II) en la nefropatía diabética. MEDIFAM 12 (2002) 421-425
36. Haffner S.M. The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. Diabetes Care 20 (1997) 469-471
37. Members of the NCEP Expert Panel. Excecutive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on Detection, Evaluation, and Treatment fo High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
38. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (CARE). N Engl J Med 335 (1996) 1001-1009
39. Pinto Sala X. Factores que condicionan la efectividad y las indicaciones de las estatinas en prevención cardiovascular. Aten Primaria 23 (1999) 228-234
40. Galeote M., Bernal E., and Pradas F. Estatinas en la prevención cardiovascular: evidencias que ayudan a mejorar la salud de los pacientes. Noticias farmacoterapéuticas 29 (2001) 4-6
41. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controled trial. Lancet 360 (2002) 7-22
42. Vinik A., and Colwell J. Effects of gemfibrozil on triglyceride levels in patients with NIDDM. Diabetes Care 16 (1993) 37-44
43. Jones P., Kafonek S.P., Laurora I., and Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81 (1998) 582-587
44. Tárraga P.J., Celada A., Cerdán M., Solera J., Ocaña J.M., and De Miguel J. Análisis coste efectividad de atorvastatina frente a simvastatina como tratamiento hipolipemiante en pacientes hipercolesterolémicos en atención primaria. Aten Primaria 27 (2001) 18-24
45. Llor C., and Hernández S. Anàlisi cost-eficàcia de les estatines comercialitzadas en el nostre país. Butlltinet, SCMFiC 19 (2001) 148-149
46. MacLeod K.M., and Tooke J.E. Direct and Indirect Costs of Cardiovascular and Cerebrovascular Complications of Type II Diabetes. PharmacoEconomics 8 Supl 1 (1995) 46-51
47. Sender Palacios M.J. Detección precoz de la retinopatía diabética en la atención primaria de salud: aplicación del método de fotografía con cámara de retina no midriática. Tesis doctoral. Universitat Autònoma de Barcelona. Bellaterra (2001)